Podium to Practice: EHA 2025 – Leukemia: BEAT AML CONSORTIUM

Podium to Practice: EHA 2025 – Leukemia: BEAT AML CONSORTIUM

Podium to Practice: EHA 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Julie Bergeron

Icon Chair Speaker

Speakers

Dr. Brian Leber

Dr. Danielle Hammond

Studies / Trials Discussed

S138 – AZACITIDINE, VENETOCLAX, AND REVUMENIB FOR NEWLY DIAGNOSED OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA (AML) AND NPM1 MUTATION OR KMT2A REARRANGEMENT: UPDATED RESULTS FROM THE BEAT AML CONSORTIUM

Studies/trials discussed:

S138 – AZACITIDINE, VENETOCLAX, AND REVUMENIB FOR NEWLY DIAGNOSED OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA (AML) AND NPM1 MUTATION OR KMT2A REARRANGEMENT: UPDATED RESULTS FROM THE BEAT AML CONSORTIUM
Tagged